» Articles » PMID: 20453062

Laforin, the Most Common Protein Mutated in Lafora Disease, Regulates Autophagy

Overview
Journal Hum Mol Genet
Date 2010 May 11
PMID 20453062
Citations 109
Authors
Affiliations
Soon will be listed here.
Abstract

Lafora disease (LD) is an autosomal recessive, progressive myoclonus epilepsy, which is characterized by the accumulation of polyglucosan inclusion bodies, called Lafora bodies, in the cytoplasm of cells in the central nervous system and in many other organs. However, it is unclear at the moment whether Lafora bodies are the cause of the disease, or whether they are secondary consequences of a primary metabolic alteration. Here we describe that the major genetic lesion that causes LD, loss-of-function of the protein laforin, impairs autophagy. This phenomenon is confirmed in cell lines from human patients, mouse embryonic fibroblasts from laforin knockout mice and in tissues from such mice. Conversely, laforin expression stimulates autophagy. Laforin regulates autophagy via the mammalian target of rapamycin kinase-dependent pathway. The changes in autophagy mediated by laforin regulate the accumulation of diverse autophagy substrates and would be predicted to impact on the Lafora body accumulation and the cell stress seen in this disease that may eventually contribute to cell death.

Citing Articles

Identification of Novel Inhibitors of Starch Excess 4 (SEX4).

Lee D, Lee D, Won K, Kim S, Kim Y Life (Basel). 2025; 14(12.

PMID: 39768393 PMC: 11678766. DOI: 10.3390/life14121686.


Dapagliflozin ameliorates Lafora disease phenotype in a zebrafish model.

Della Vecchia S, Imbrici P, Liantonio A, Naef V, Damiani D, Licitra R Biomed Pharmacother. 2025; 183:117800.

PMID: 39753095 PMC: 11794196. DOI: 10.1016/j.biopha.2024.117800.


Neuromuscular junction dysfunction in Lafora disease.

Shukla M, Chugh D, Ganesh S Dis Model Mech. 2024; 17(10).

PMID: 39301689 PMC: 11512103. DOI: 10.1242/dmm.050905.


Gene therapy for Lafora disease in the Epm2a mouse model.

Zafra-Puerta L, Iglesias-Cabeza N, Burgos D, Sciaccaluga M, Gonzalez-Fernandez J, Bellingacci L Mol Ther. 2024; 32(7):2130-2149.

PMID: 38796707 PMC: 11286821. DOI: 10.1016/j.ymthe.2024.05.032.


The impact of nanomaterials on autophagy across health and disease conditions.

Florance I, Cordani M, Pashootan P, Moosavi M, Zarrabi A, Chandrasekaran N Cell Mol Life Sci. 2024; 81(1):184.

PMID: 38630152 PMC: 11024050. DOI: 10.1007/s00018-024-05199-y.


References
1.
Fuertes G, de Llano J, Villarroya A, Rivett A, Knecht E . Changes in the proteolytic activities of proteasomes and lysosomes in human fibroblasts produced by serum withdrawal, amino-acid deprivation and confluent conditions. Biochem J. 2003; 375(Pt 1):75-86. PMC: 1223664. DOI: 10.1042/BJ20030282. View

2.
Korolchuk V, Mansilla A, Menzies F, Rubinsztein D . Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell. 2009; 33(4):517-27. PMC: 2669153. DOI: 10.1016/j.molcel.2009.01.021. View

3.
Serratosa J, Gomez-Garre P, Gallardo M, Anta B, de Bernabe D, Lindhout D . A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Hum Mol Genet. 1999; 8(2):345-52. DOI: 10.1093/hmg/8.2.345. View

4.
Chan E, Omer S, Ahmed M, Bridges L, Bennett C, Scherer S . Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus. Neurology. 2004; 63(3):565-7. DOI: 10.1212/01.wnl.0000133215.65836.03. View

5.
Ganesh S, Delgado-Escueta A, Suzuki T, Francheschetti S, Riggio C, Avanzini G . Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype. Hum Mol Genet. 2002; 11(11):1263-71. DOI: 10.1093/hmg/11.11.1263. View